BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 24222661)

  • 1. Low levels of circulating estrogen sensitize PTEN-null endometrial tumors to PARP inhibition in vivo.
    Janzen DM; Paik DY; Rosales MA; Yep B; Cheng D; Witte ON; Kayadibi H; Ryan CM; Jung ME; Faull K; Memarzadeh S
    Mol Cancer Ther; 2013 Dec; 12(12):2917-28. PubMed ID: 24222661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells.
    Miyasaka A; Oda K; Ikeda Y; Wada-Hiraike O; Kashiyama T; Enomoto A; Hosoya N; Koso T; Fukuda T; Inaba K; Sone K; Uehara Y; Kurikawa R; Nagasaka K; Matsumoto Y; Arimoto T; Nakagawa S; Kuramoto H; Miyagawa K; Yano T; Kawana K; Osuga Y; Fujii T
    BMC Cancer; 2014 Mar; 14():179. PubMed ID: 24625059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
    Bian X; Gao J; Luo F; Rui C; Zheng T; Wang D; Wang Y; Roberts TM; Liu P; Zhao JJ; Cheng H
    Oncogene; 2018 Jan; 37(3):341-351. PubMed ID: 28945226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors.
    Philip CA; Laskov I; Beauchamp MC; Marques M; Amin O; Bitharas J; Kessous R; Kogan L; Baloch T; Gotlieb WH; Yasmeen A
    BMC Cancer; 2017 Sep; 17(1):638. PubMed ID: 28886696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors.
    Dedes KJ; Wetterskog D; Mendes-Pereira AM; Natrajan R; Lambros MB; Geyer FC; Vatcheva R; Savage K; Mackay A; Lord CJ; Ashworth A; Reis-Filho JS
    Sci Transl Med; 2010 Oct; 2(53):53ra75. PubMed ID: 20944090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells.
    Minami D; Takigawa N; Takeda H; Takata M; Ochi N; Ichihara E; Hisamoto A; Hotta K; Tanimoto M; Kiura K
    Mol Cancer Res; 2013 Feb; 11(2):140-8. PubMed ID: 23239809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of Olaparib (AZD2281) potentiates SN-38 cytotoxicity in colon cancer cells by indirect inhibition of Rad51-mediated repair of DNA double-strand breaks.
    Tahara M; Inoue T; Sato F; Miyakura Y; Horie H; Yasuda Y; Fujii H; Kotake K; Sugano K
    Mol Cancer Ther; 2014 May; 13(5):1170-80. PubMed ID: 24577941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer.
    Forster MD; Dedes KJ; Sandhu S; Frentzas S; Kristeleit R; Ashworth A; Poole CJ; Weigelt B; Kaye SB; Molife LR
    Nat Rev Clin Oncol; 2011 May; 8(5):302-6. PubMed ID: 21468130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of Rad51 sensitizes breast cancer cells with wild-type PTEN to olaparib.
    Zhao Q; Guan J; Zhang Z; Lv J; Wang Y; Liu L; Zhou Q; Mao W
    Biomed Pharmacother; 2017 Oct; 94():165-168. PubMed ID: 28759753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
    Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
    Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
    Ning J; Wakimoto H; Peters C; Martuza RL; Rabkin SD
    J Natl Cancer Inst; 2017 Mar; 109(3):1-13. PubMed ID: 28376211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer.
    García-Parra J; Dalmases A; Morancho B; Arpí O; Menendez S; Sabbaghi M; Zazo S; Chamizo C; Madoz J; Eroles P; Servitja S; Tusquets I; Yelamos J; Lluch A; Arribas J; Rojo F; Rovira A; Albanell J
    Eur J Cancer; 2014 Oct; 50(15):2725-34. PubMed ID: 25128455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
    Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
    Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer.
    Gunderson CC; Moore KN
    Future Oncol; 2015; 11(5):747-57. PubMed ID: 25757679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An olaparib window-of-opportunity trial in patients with early-stage endometrial carcinoma: POLEN study.
    Romero I; Rubio MJ; Medina M; Matias-Guiu X; Santacana M; Schoenenberger JA; Guerra EM; Cortés A; Minig L; Coronado P; Cueva JF; Gómez L; Malfettone A; Sampayo M; Llombart-Cussac A; Poveda A
    Gynecol Oncol; 2020 Dec; 159(3):721-731. PubMed ID: 32988624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI).
    Banerjee S; Stewart J; Porta N; Toms C; Leary A; Lheureux S; Khalique S; Tai J; Attygalle A; Vroobel K; Lord CJ; Natrajan R; Bliss J
    Int J Gynecol Cancer; 2021 Nov; 31(11):1471-1475. PubMed ID: 34518240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PARP is activated in human asthma and its inhibition by olaparib blocks house dust mite-induced disease in mice.
    Ghonim MA; Pyakurel K; Ibba SV; Wang J; Rodriguez P; Al-Khami AA; Lammi MR; Kim H; Zea AH; Davis C; Okpechi S; Wyczechowska D; Al-Ghareeb K; Mansy MS; Ochoa A; Naura AS; Boulares AH
    Clin Sci (Lond); 2015 Dec; 129(11):951-62. PubMed ID: 26205779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel dopamine receptor D2 antagonist (ONC206) potentiates the effects of olaparib in endometrial cancer.
    Paraghamian SE; Qiu J; Hawkins GM; Zhao Z; Sun W; Fan Y; Zhang X; Suo H; Hao T; Prabhu VV; Allen JE; Zhou C; Bae-Jump V
    Cancer Biol Ther; 2023 Dec; 24(1):2202104. PubMed ID: 37069726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanoformulation of Olaparib Amplifies PARP Inhibition and Sensitizes
    van de Ven AL; Tangutoori S; Baldwin P; Qiao J; Gharagouzloo C; Seitzer N; Clohessy JG; Makrigiorgos GM; Cormack R; Pandolfi PP; Sridhar S
    Mol Cancer Ther; 2017 Jul; 16(7):1279-1289. PubMed ID: 28500233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.